Sanuwave Health (SNWV) Stock Price, News & Analysis

Company Overview

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.

Key Stats

• Today's Range: $35.75 to $38.00
• 50-Day Range: $29.70 to $42.74
• 52-Week Range: $5.21 to $46.58
• Volume: 55,094 shs
• Average Volume: 51,990 shs
• Market Capitalization: $314.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $49.00
• Consensus Rating: Buy

Sanuwave Health Stock Analysis - MarketRank™

Sanuwave Health scored higher than 50% of companies evaluated by MarketBeat, and ranked 579th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Sanuwave Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Sanuwave Health has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Sanuwave Health is -4.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sanuwave Health is -4.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for SNWV.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sanuwave Health does not currently pay a dividend.

Dividend Growth

Sanuwave Health does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for SNWV.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Sanuwave Health has a news sentiment score of 1.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.

MarketBeat Follows

1 people have added Sanuwave Health to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Sanuwave Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $51,596.00 in company stock.

Percentage Held by Insiders

14.90% of the stock of Sanuwave Health is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

42.53% of the stock of Sanuwave Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SNWV Stock Analysis - Frequently Asked Questions

How have SNWV shares performed this year?

Sanuwave Health's stock was trading at $37.61 at the beginning of the year. Since then, SNWV shares have decreased by 1.8% and is now trading at $36.94.

How were Sanuwave Health's earnings last quarter?

Sanuwave Health Inc. (NASDAQ:SNWV) posted its quarterly earnings results on Friday, August, 8th. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.09) by $0.10. The firm had revenue of $10.16 million for the quarter, compared to analyst estimates of $10.14 million.
Read the conference call transcript.

Who are Sanuwave Health's major shareholders?

Sanuwave Health's top institutional investors include Opaleye Management Inc. (11.44%), AWM Investment Company Inc. (5.71%), Geode Capital Management LLC (1.84%) and Bank of America Corp DE (0.38%). Insiders that own company stock include Peter Stegagno and Iulian Cioanta.
View institutional ownership trends.

How do I buy shares of Sanuwave Health?

Shares of SNWV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/08/2025
• Today: 8/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:SNWV
• Previous Symbol: NASDAQ:SNWV
• CIK: 1417663
• Web: N/A
• Phone: (770) 419-7525
• Fax: 770-419-8634
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Sanuwave Health: $49.00
• High Price Target: $49.00
• Low Price Target: $49.00
• Potential Upside/Downside: +27.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($8.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$31.37 million
• Net Margins: -97.03%
• Pretax Margin: -96.96%
• Return on Equity: N/A
• Return on Assets: -135.15%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.43
• Quick Ratio: 0.31

Sales & Book Value

• Annual Sales: $32.63 million
• Price / Sales: 10.07
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.49) per share
• Price / Book: -25.74

Miscellaneous

• Outstanding Shares: 8,570,000
• Free Float: 7,291,000
• Market Cap: $328.75 million
• Optionable: N/A
• Beta: 1.29